Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $22.9552W HIGH $42.81
Volume
1.53 M
Value Traded
79.66 M
Short % Float
9.23%
-0.73%Week
+1.96%1 Month
-12.47%3 Month
+16.08%6 Month
+249.12%5 Year
+247.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.18 B
EPS (TTM)
3.02
P/E Ratio
11.75
Ent. Value
4.45 B
Total Shares
118.03 M
Float Shares
121.03 M
Insiders
3.00%
Institutions
95.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
INDV Catalyst Timeline
Dated clinical, regulatory and corporate events for Indivior Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Indivior Pharmaceuticals, Inc.
283Total events
6Upcoming
95Tier-1 (high impact)
2015 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Timing GuidancePresentation
Board of Directors declared special cash dividend of $8.13 per share
▲Corporate ApprovalCorporate
Indivior Board declares special cash dividend of $8.13 per share contingent on Merger closing
●FDA Filing AcceptedRegulatory Filing
Indivior filed joint proxy statement/prospectus with SEC
●Corporate ApprovalCorporate
Indivior filed joint proxy statement/prospectus with SEC for the Merger
▲Full ResultsSublocadeApprovedClinical Data
Two real-world evidence studies published showing adherence to SUBLOCADE associated with lower relapse risk and reduced healthcare utilization
opioid use disordersource ↗
▼Program DiscontinuationINDV-6001DiscontinuedCorporate
Indivior will not pursue Phase 3 development of INDV-6001; amended license with Alar Pharmaceuticals
opioid use disordersource ↗
▼Primary Endpoint MissedINDV-2000DiscontinuedClinical Data
INDV-2000 (Rocavorexant) did not meet primary endpoint of 'no treatment failure' in Phase 2 POC study
opioid use disordersource ↗
▼Program DiscontinuationINDV-2000DiscontinuedCorporate
Indivior will not advance INDV-2000 internally
opioid use disordersource ↗
▲PublicationSublocadeApprovedPresentation
Cost impact model published in The Journal of Current Medical Research and Opinion
opioid use disordersource ↗
▲Full ResultsSublocadeApprovedClinical Data
Results from randomized double-blind trial of SUBLOCADE 100 mg and 300 mg monthly maintenance doses published in JAMA Network Open
moderate-to-severe opioid use disordersource ↗
◆Oral PresentationPresentation
Indivior to participate in Piper Sandler 37th Annual Healthcare Conference
◆Timing GuidanceSublocadeApprovedPresentation
SUBLOCADE net revenue run rate target of $1 billion by end of 2025
opioid use disordersource ↗
▲Poster PresentationSublocadeApprovedPresentation
Three posters presented at AMCP Nexus 2025 on real-world evidence for SUBLOCADE
opioid use disordersource ↗
▲Full ResultsSublocadeApprovedClinical Data
Results from multicenter open-label trial published in JAMA Network Open showing rapid induction with SUBLOCADE improves retention
opioid use disordersource ↗
◆Last Patient Last VisitINDV-6001DiscontinuedTrial
Last Patient Last Visit for INDV-6001 (3-month long-acting buprenorphine)
Opioid Use Disordersource ↗
●Other Regulator MilestoneEx-US Regulatory
Cancellation of secondary listing on London Stock Exchange
◆Restructuring LayoffsCorporate
Intention to cancel secondary listing on London Stock Exchange
▲Full ResultsSublocadeApprovedClinical Data
Real-world study published in Drug and Alcohol Dependence Reports showing BUP-XR reduced odds of ED visits
opioid use disordersource ↗
◆Management ChangeCorporate
Appointment of Vanessa Procter as Executive Vice President of Corporate Affairs
◆Oral PresentationPresentation
Northland Capital Markets Conference virtual 1x1/group meetings
◆Oral PresentationSublocadeApprovedPresentation
Presentation of post hoc analysis of SUBLOCADE 300 mg vs 100 mg in high fentanyl users at CPDD
opioid use disordersource ↗
▲PublicationSublocadeApprovedPresentation
Publication of study 'Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder During Pregnancy' in American Journal on Addictions
opioid use disorder during pregnancy and postpartumsource ↗
◆Management ChangeCorporate
Mark Crossley stepping down as CEO, expected to remain until at least AGM in May 2025
Past FDA Catalysts and PDUFA Decisions
How INDV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-02-21 | Sublocade (buprenorphine) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C42 / 100
Pipeline Score
$182M
Pipeline Value
$5.8B
Commercial Value
Fair Value
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 34%
Small Cap(rank 224 of 658)
Percentile Rank
Indivior Pharmaceuticals, Inc. carries a moderate pipeline score (42/100), with $561M risk-adjusted pipeline value, led by INDV-2000 in Healthy (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $1.3B x 4.4 = $5.8B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Sublocade | $957M | $770M | +24.3% |
| Sublingual & other | $226M | $231M | -2.2% |
| PERSERIS | $22M | $29M | -24.1% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INDV-2000 Small moleculeCompletedNCT06384157 | Opioid Use Disorder | Phase 2 | COMPLETED | 300 | Nov 3, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every INDV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SUBLOCADE Priority | opioid use disorder | 2025-12-17 | more than 43 instances per week at screening to fewer than three instances per week by week three; higher opioid abstinence rates with 300-mg dose compared to 100 mgRead More | New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk PopulationsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Anderson Woodrow DOfficer (Chief Accounting Officer) | Buy | 1,500 27,638 held | $35.69 | 08/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INDV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 1.5 % | 43.66 M | 1.06 M |
INDV Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INDV ranks across every disease it competes in
Competitive Position is a premium feature
See how INDV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINDV News
INDVIndivior Pharmaceuticals, Inc. Declares Special Cash Dividend
Indivior Pharmaceuticals has declared a special cash dividend of $8.13 per share, contingent upon the successful completion of its merger with Supernus Pharmaceuticals, expected around November 2, 2026. Shareholders of record as of October 30, 2026, will receive this dividend, which highlights Indivior's strong financial position. However, if the merger does not close, the dividend will not be paid.
Read more →INDV▼ -6.6%on this news
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Indivior reported strong financial results for the second quarter of 2026, with total net revenue reaching $343 million, a 14% increase compared to the previous year. The company's SUBLOCADE® product achieved record net revenue of $253 million, reflecting a 21% year-over-year growth. Additionally, both GAAP and non-GAAP net income reached record levels, indicating robust financial performance.
Read more →INDV▼ -6.6%on this newsshared move
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Indivior Pharmaceuticals announced a merger with Supernus Pharmaceuticals, aiming to create a leading CNS biopharmaceutical company. This merger is expected to enhance their market presence and operational scale. Additionally, new studies highlight the effectiveness of SUBLOCADE®, an injectable treatment for opioid use disorder, in improving patient adherence.
Read more →INDVIndivior to Report Second Quarter 2026 Financial Results and Host Webcast
Indivior Pharmaceuticals will report its second quarter 2026 financial results on August 4, 2026, at 7:00 a.m. EDT. Following the results, CEO Joe Ciaffoni and the leadership team will host a live webcast at 8:00 a.m. EDT. The event will be accessible via the company's website, and a replay will be available afterward.
Read more →INDVNew Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
Indivior Pharmaceuticals announced findings from two studies indicating that adherence to monthly injectable buprenorphine is linked to lower relapse rates and reduced healthcare utilization among individuals with opioid use disorder. The studies revealed that patients using this treatment had significantly fewer infections and hospital visits compared to those on daily oral buprenorphine. These results underscore the importance of sustained treatment in managing opioid use disorder effectively.
Read more →INDVIndivior to Participate in Upcoming Investor Conferences
Indivior Pharmaceuticals, Inc. will participate in two upcoming investor conferences: the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8th. CEO Joe Ciaffoni and CFO Ryan Preblick will host meetings and a fireside chat at these events. The company's commitment to treating opioid use disorder is emphasized.
Read more →INDVIndivior Announces $175 Million Accelerated Share Repurchase
Indivior Pharmaceuticals has announced a $175 million accelerated share repurchase agreement with Barclays Bank. This move is part of a larger $400 million share repurchase program, showcasing the company's confidence in its financial health and strategic direction. The ASR is expected to result in the repurchase of approximately 3.7 million shares, with final settlement anticipated by the end of June 2026.
Read more →INDV▲ +7.7%on this newsshared move
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Indivior Pharmaceuticals reported a strong financial performance for Q1 2026, with total net revenue reaching $317 million, a 19% increase year-over-year. The company raised its full-year guidance, driven by a 32% growth in SUBLOCADE net revenue. However, it announced the discontinuation of Phase 3 development for INDV-6001 and will not advance INDV-2000 internally. The company remains focused on enhancing shareholder value through strategic capital deployment.
Read more →INDVIndivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
Indivior Pharmaceuticals presented new data at the ASAM Annual Conference highlighting the benefits of monthly injectable buprenorphine for opioid use disorder (OUD). The studies suggest that remission should be recognized as a treatment outcome, showing improvements in quality of life and reduced overdose risks. The findings reinforce the importance of sustained treatment for meaningful recovery.
Read more →INDVSurvey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
Indivior PLC announced findings from a national survey indicating that correctional facility leaders see long-acting injectable buprenorphine as a promising solution to reduce medication diversion for opioid use disorder. The survey, involving 180 professionals, revealed strong support for this treatment method, although barriers such as cost and staffing issues persist. The insights emphasize the need for improved care coordination and sustainable treatment delivery in correctional settings.
Read more →INDVIndivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
Indivior Pharmaceuticals, Inc. will report its first quarter 2026 financial results on April 30, 2026. Following the report, CEO Joe Ciaffoni and the leadership team will host a live webcast at 8:00 a.m. U.S. EDT. The event will be accessible via the company's website, promoting transparency with investors.
Read more →INDV▲ +5.9%on this news
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
Indivior Pharmaceuticals has published a cost impact model indicating that SUBLOCADE, a monthly injectable buprenorphine, may significantly reduce staffing needs and associated costs in correctional facilities compared to other opioid use disorder treatments. The model estimates substantial savings and highlights the potential for improved operational efficiency in jails and prisons. However, the study has limitations, including the exclusion of medication acquisition costs.
Read more →INDVNational Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
A recent survey by Indivior reveals that only 58% of U.S. correctional facilities provide medications for opioid use disorder (MOUD), with significant regional disparities. Jails are more likely to offer MOUD than prisons, and facilities in the South report the lowest access rates. The study emphasizes the need for improved continuity of care and support systems for individuals with opioid use disorder post-incarceration.
Read more →INDVIndivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - March 12, 2026
Indivior Pharmaceuticals announced the pricing of its upsized $450 million convertible senior notes offering, which is expected to close on March 17, 2026. The notes will accrue interest at 0.625% and mature in 2031, with specific conditions for conversion. The proceeds will be used for debt repayment, share repurchases, and general corporate purposes.
Read more →INDVIndivior Reports Fourth Quarter and Full-Year 2025 Financial Results
Indivior Pharmaceuticals reported strong financial results for Q4 and full year 2025, highlighting a 13% increase in SUBLOCADE net revenue and a 20% rise in adjusted EBITDA. The company is now executing Phase II of its Action Agenda, focusing on accelerating growth and enhancing cash flow in 2026. Strategic capital deployment plans include managing debt and a new share repurchase program.
Read more →INDVIndivior Reports Fourth Quarter and Full-Year 2025 Financial Results
Indivior Pharmaceuticals reported strong financial results for Q4 and full-year 2025, highlighting a 13% increase in SUBLOCADE net revenue and a 20% rise in adjusted EBITDA. The company is now executing Phase II of its Action Agenda, aiming to accelerate growth and cash flow in 2026. Indivior also completed its corporate domicile change to the U.S., enhancing its operational focus.
Read more →INDVIndivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
Indivior Pharmaceuticals announced it will report its fourth quarter and full-year 2025 financial results on February 26, 2026. Following the results, a live webcast presentation will be held featuring CEO Joe Ciaffoni and other leadership team members. The event aims to provide insights into the company’s performance and future direction.
Read more →INDVIndivior Announces Completion of Redomiciliation to the United States
Indivior Pharmaceuticals has successfully completed its redomiciliation from the UK to the US, establishing a new parent company, Indivior Pharmaceuticals, Inc. The transition, approved by shareholders, aims to leverage the benefits of a U.S. stock listing. The company anticipates improved corporate governance and enhanced collaboration in addressing opioid use disorder.
Read more →About Indivior Pharmaceuticals, Inc.
Headquarters10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD, VA, 23235
BIOPHARMAWATCH ELITE PLUS
Trade the next INDV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime